Kukje Pharmaceutical said Tuesday that it has signed an agreement to supply its Cephalosporin Inj. exclusively to New-In, a Taiwanese company.

The company signed the accord during the CPHI China 2018 convention. Kukje promoted its cephalosporin antibiotics and eye drop solution during the fair. The contract is the second supply agreement that Kukje signed with New-In as the two companies signed an exclusive deal for Flomox, an antibiotic solution, in March.

Kukje expects that Taiwan will become a new market for Korean small and medium-sized pharmaceutical companies, which have mostly been dependent on Southeast Asian export.

The company has also concluded a basic agreement for export and licensing agreements with various Chinese companies for several of its new eye drop solutions.

“We plan to continue to challenge the global market and actively pioneer overseas marketing and marketing investment,” a company official said.

corea022@docdocdoc.co.kr

<© Korea Biomedical Review, All rights reserved.>